Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Immunic ( (IMUX) ) is now available.
On May 19, 2026, Immunic announced that veteran biopharmaceutical executive Michael W. Bonney was appointed Chair of its Board of Directors, effective May 16, 2026, with former interim chair Simona Skerjanec remaining on the board. Bonney brings more than 30 years of commercial and leadership experience, including key roles in the launch and success of Biogen’s Avonex for multiple sclerosis and a decade leading Cubist Pharmaceuticals through strong growth and its $9.5 billion sale to Merck.
The appointment underscores Immunic’s push to strengthen governance and commercial expertise as it advances its lead MS therapy, vidofludimus calcium, through phase 3 trials and prepares for potential regulatory approvals and commercialization. Management highlighted Bonney’s track record in building neurology and anti-infective franchises, extensive board experience across major biopharma names, and his expected role in guiding Immunic’s transition from a development-stage biotech to a fully integrated commercial-stage company.
The most recent analyst rating on (IMUX) stock is a Buy with a $56.00 price target. To see the full list of analyst forecasts on Immunic stock, see the IMUX Stock Forecast page.
Spark’s Take on IMUX Stock
According to Spark, TipRanks’ AI Analyst, IMUX is a Neutral.
The score is mainly held back by weak financial performance (no revenue, large ongoing losses, and sustained cash burn). Technicals are notably positive with price above major moving averages and supportive momentum, while valuation remains constrained by negative earnings and lack of dividend support. Corporate events modestly improve the outlook by reducing listing risk and strengthening leadership depth.
To see Spark’s full report on IMUX stock, click here.
More about Immunic
Immunic, Inc., listed on Nasdaq as IMUX, is a late-stage biotechnology company developing novel oral therapies for neurologic diseases, with a primary focus on multiple sclerosis. Its lead candidate, vidofludimus calcium (IMU-838), is in phase 3 trials for relapsing multiple sclerosis after showing activity in earlier-stage studies across relapsing-remitting and progressive forms of MS, and the company is also advancing earlier pipeline assets targeting neurodegenerative and chronic inflammatory conditions.
Vidofludimus calcium acts as a first-in-class Nurr1 activator with additional anti-inflammatory and anti-viral effects via selective DHODH inhibition, positioning Immunic to build a broader therapeutics platform in neurodegenerative, chronic inflammatory and autoimmune-related diseases. The company is working toward transitioning into a fully integrated commercial-stage organization as it approaches key late-stage clinical and regulatory milestones expected by the end of 2026.
Average Trading Volume: 298,242
Technical Sentiment Signal: Hold
Current Market Cap: $164.5M
Find detailed analytics on IMUX stock on TipRanks’ Stock Analysis page.